-
Anokion Announces New Data from the Phase 1 MoveS-it Study Supporting ANK-700 as a Novel, Potential Disease Modifying Treatment for Relapsing-Remitting Multiple Sclerosis | Morningstar
المصدر: Buzz FX / 18 سبتمبر 2024 03:30:16 America/New_York
[Business Wire](/news/business-wire) Anokion Announces New Data from the Phase 1 MoveS-it Study Supporting ANK-700 as a Novel, Potential Disease Modifying Treatment for Relapsing-Remitting Multiple Sclerosis Anokion Announces New Data from
Read more...